Why is a successful engineering batch not by itself evidence of validated routine manufacture?

Why

Engineering or demonstration batches are valuable. They test equipment settings, scale-up assumptions and sampling plans before PPQ. But the FDA's 2011 guidance says PPQ lots should be made under normal conditions by the personnel routinely expected to do each step, with routine utilities, materials, environment and procedures, following an approved protocol.

Annex 15 similarly expects validation batches at commercial scale, made by trained staff using approved documentation under GMP, with production staff involved. An engineering batch typically differs in several ways. Development scientists may run it, adjusting parameters in real time.

Raw materials may be a single favorable lot. Sampling may be limited or not predefined. GMP documentation may be partial.

And one batch says nothing about between-batch variability. Consider a bioreactor engineering run that hits target titer with a process development team on site. The first PPQ run, with the manufacturing shift and a new media lot, may show lower titer because a feed was timed differently.

The engineering run did its job by revealing settings, but it is not proof of consistency. Engineering data can still support validation as part of the cumulative knowledge the FDA guidance says should establish PPQ conditions, as long as their limitations are stated.